Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Globe Newswire (Tue, 10-Feb 4:05 PM ET)
AI Diagnostics: The End of the High-Cost Imaging Era
Globe Newswire (Fri, 16-Jan 11:40 AM ET)
Globe Newswire (Mon, 5-Jan 8:00 AM ET)
Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Globe Newswire (Tue, 30-Dec 4:05 PM ET)
Market Chameleon (Tue, 9-Dec 6:47 AM ET)
Global AI Infrastructure Shift Ignites Biotech Growth Phase
Globe Newswire (Tue, 9-Dec 9:25 AM ET)
Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution
Globe Newswire (Tue, 9-Dec 8:00 AM ET)
Ceribell Receives FDA 510(k) Clearance for Use of Clarity? Algorithm for Neonates
Globe Newswire (Mon, 24-Nov 8:00 AM ET)
Ceribell to Participate in the Piper Sandler 37th Annual Healthcare Conference
Globe Newswire (Wed, 19-Nov 4:05 PM ET)
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.
Ceribell trades on the NASDAQ stock market under the symbol CBLL.
As of February 17, 2026, CBLL stock price climbed to $19.85 with 115,947 million shares trading.
CBLL has a beta of 0.49, meaning it tends to be less sensitive to market movements. CBLL has a correlation of 0.02 to the broad based SPY ETF.
CBLL has a market cap of $736.35 million. This is considered a Small Cap stock.
Last quarter Ceribell reported $23 million in Revenue and -$.37 earnings per share. This beat revenue expectation by $807,130 and exceeded earnings estimates by $.05.
The top ETF exchange traded funds that CBLL belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
CBLL has underperformed the market in the last year with a price return of -9.4% while the SPY ETF gained +13.3%. However, in the short term, CBLL had mixed performance relative to the market. It has outperformed in the last 3 months, returning +58.9% vs +2.0% return in SPY. But in the last 2 weeks, CBLL shares have been beat by the market, returning -3.7% compared to an SPY return of -1.2%.
CBLL support price is $19.16 and resistance is $20.38 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CBLL shares will trade within this expected range on the day.
